Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CX-046684 + CX-051869
- Development stage
- Approved
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**CX-046684 + CX-051869** is a two-component mRNA COVID-19 vaccine substance presentation associated with Moderna's updated Spikevax formulations. The components are distinct mRNA active substances encoding prefusion-stabilized SARS-CoV-2 spike antigens from different Omicron-lineage variants: CX-046684 encodes a KP.2 spike antigen and CX-051869 encodes an LP.8.1 spike antigen. Public labeling shows these as ingredient-level substances used in successive seasonal Spikevax formulations rather than as a distinct, co-formulated branded product with its own separate nonproprietary name. As an mRNA vaccine, its pharmacology is based on intracellular expression of viral spike antigen after intramuscular administration, inducing neutralizing antibody and cellular immune responses for prevention of COVID-19.
- Other names
- covid-19 vaccine, mrna
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on CX-046684 + CX-051869.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CX-046684 + CX-051869.